What SEC filings does Ironwood Pharmaceuticals, Inc. submit to the SEC?

Ironwood Pharmaceuticals, Inc. (IRWD) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about IRWD?

A Form 4 for IRWD discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Ironwood Pharmaceuticals, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for IRWD?

The 10-K is Ironwood Pharmaceuticals, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all IRWD SEC filings directly on EDGAR?

You can view all historical Ironwood Pharmaceuticals, Inc. filings on the SEC EDGAR company page for IRWD. Each filing card on this page links directly to the original SEC document.

How often does Ironwood Pharmaceuticals, Inc. file with the SEC?

Ironwood Pharmaceuticals, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling IRWD shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

IRWD SEC Filing News — Ironwood Pharmaceuticals, Inc.

Latest SEC filings for Ironwood Pharmaceuticals, Inc. (IRWD) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-16.

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA name…

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Market Cap: $582.5M CIK: 1446847

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for IRWD currently lean bearish. Of the 20 filing records displayed, 2 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

IRWD Filing Activity Snapshot 2026-05-21 — 2026-10-16

Insider Transactions (Form 4)

0 buys vs 2 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$578.1K

Silver Ronald (PFO & PAO) · 2026-07-09

127,890 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Ironwood Pharmaceuticals, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 9 compensation award and 2 open-market sale. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×9: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×2: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Compensation award Tax / Compensation Filing 2026-09-17

IRWD insider Form 4 filed for equity award, exercise, or tax withholding

DENNER ALEXANDER J (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	3,694	—	—

Filing: Form 4 (Insider Transaction) Insider: DENNER ALEXANDER J (Director) Shares: 3,694

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-22

IRWD insider Form 4 filed for equity award, exercise, or tax withholding

Silber Jeffrey (SVP, CMO, Head-Res&Drug) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	137,036	—	—

Filing: Form 4 (Insider Transaction) Insider: Silber Jeffrey (SVP, CMO, Head-Res&Drug) Shares: 137,036

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-09

IRWD insider Silver Ronald (PFO & PAO) sold 127,890 shares (~$578.1K)

Silver Ronald, listed as PFO & PAO at IRONWOOD PHARMACEUTICALS INC, reported an open-market sale of 127,890 IRWD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	127,890	$4.52	$578.1K

Filing: Form 4 (Insider Transaction) Insider: Silver Ronald (PFO & PAO) Shares: 127,890 Est. Value: $578.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-17

IRWD insider Form 4 filed for equity award, exercise, or tax withholding

Shepard Jay (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	63,481	—	—

Filing: Form 4 (Insider Transaction) Insider: Shepard Jay (Director) Shares: 63,481

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-17

IRWD insider Form 4 filed for equity award, exercise, or tax withholding

Kessler Marla L (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	63,481	—	—

Filing: Form 4 (Insider Transaction) Insider: Kessler Marla L (Director) Shares: 63,481

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-17

IRWD insider Form 4 filed for equity award, exercise, or tax withholding

Currie Mark G (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	63,481	—	—

Filing: Form 4 (Insider Transaction) Insider: Currie Mark G (Director) Shares: 63,481

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-17

IRWD insider Form 4 filed for equity award, exercise, or tax withholding

Duane Jon R (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	63,481	—	—

Filing: Form 4 (Insider Transaction) Insider: Duane Jon R (Director) Shares: 63,481

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-17

IRWD insider Form 4 filed for equity award, exercise, or tax withholding

DENNER ALEXANDER J (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	4,065	—	—
`A`	Compensation award	63,481	—	—

Filing: Form 4 (Insider Transaction) Insider: DENNER ALEXANDER J (Director) Shares: 67,546

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-17

IRWD insider McHugh Julie (Director) sold 21,571 shares (~$80.5K)

McHugh Julie, listed as Director at IRONWOOD PHARMACEUTICALS INC, reported an open-market sale of 21,571 IRWD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	63,481	—	—
`S`	Open-market sale	21,571	$3.73	$80.5K

Filing: Form 4 (Insider Transaction) Insider: McHugh Julie (Director) Shares: 21,571 Est. Value: $80.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-17

IRWD insider Form 4 filed for equity award, exercise, or tax withholding

Moukheibir Catherine (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	63,481	—	—

Filing: Form 4 (Insider Transaction) Insider: Moukheibir Catherine (Director) Shares: 63,481

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-21

IRWD insider Form 4 filed for equity award, exercise, or tax withholding

Silver Ronald (PFO & PAO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	25,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Silver Ronald (PFO & PAO) Shares: 25,000

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Ironwood Pharmaceuticals, Inc. has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-23

IRWD Form 144 filed for proposed insider sale by Shetzline Michael (83,306 shares) ~$377.4K

Shetzline Michael filed a Form 144 with the SEC indicating intent to sell IRWD (IRONWOOD PHARMACEUTICALS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Shetzline Michael Shares: 83,306 Est. Value: $377.4K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-07

IRWD Form 144 filed for proposed insider sale by RONALD SILVER (127,890 shares) ~$560.2K

RONALD SILVER filed a Form 144 with the SEC indicating intent to sell IRWD (IRONWOOD PHARMACEUTICALS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: RONALD SILVER Shares: 127,890 Est. Value: $560.2K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-16

IRWD Form 144 filed for proposed insider sale by JULIE MCHUGH (21,571 shares) ~$79.6K

JULIE MCHUGH filed a Form 144 with the SEC indicating intent to sell IRWD (IRONWOOD PHARMACEUTICALS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JULIE MCHUGH Shares: 21,571 Est. Value: $79.6K

View on SEC EDGAR → Open Filing Document →

Material Events 5 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 5 in this period for Ironwood Pharmaceuticals, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-16

IRWD filed 8-K — material company event

IRONWOOD PHARMACEUTICALS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-06

IRWD filed 8-K — material company event

IRONWOOD PHARMACEUTICALS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-18

IRWD filed 8-K — material company event

IRONWOOD PHARMACEUTICALS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-15

IRWD filed 8-K — material company event

IRONWOOD PHARMACEUTICALS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K/A Amended Material Company Update 2026-05-21

IRWD filed amended 8-K — material company event

IRONWOOD PHARMACEUTICALS INC filed an amended 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K/A (Material Event Amendment)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Ironwood Pharmaceuticals, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

IRWD filed Quarterly Report (10-Q)

IRONWOOD PHARMACEUTICALS INC filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Ironwood Pharmaceuticals, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on IRWD. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — IRWD SEC Filings

More Tools for IRWD

IRWD Full Stock Analysis IRWD Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper IRWD analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the IRWD stock analysis page.

IRWD Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer